Oncology Medical News about locally advanced squamous cell carcinoma of the head and neck;radiochemotherapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Radiochemotherapy in locally advanced squamous cell carcinomas of the head and neck
Clinical Oncology, 06/24/09

Matzinger O et al. - In a review of radiochemotherapy in locally advanced squamous cell carcinomas of the head and neck (SCCHN), this overview reviews the most relevant published studies on the multidisciplinary management of SCCHN and discusses future strategies to reduce locoregional failures.

Methods

SCCHN is a common disease that develops in the upper aerodigestive epithelium.
Most important risk factors are tobacco and alcohol consumption.
There is increasing evidence that human papillomavirus plays an important role in the cause of SCCHN.
The complex anatomy, the vital functions of the upper aerodigestive tract, and close proximity to vital structures, explain that the goal of treatment is not only to improve survival outcomes, but also to preserve organ function.

Results

Radiotherapy and surgery are standard modalities of treatment, reflecting the locoregional predominance of SCCHN.
Chemotherapy plays an important role in treatment of pts with locoregionally advanced disease, in conjunction with radiotherapy and surgery.
Standard therapy for resectable locoregionally advanced (stage III or IV) SCCHN cancers consists either of surgery and adjuvant chemoradiotherapy or definitive concomitant chemoradiotherapy, depending upon disease site, stage and resectability of the tumour, or institutional experience.
Concomitant chemoradiotherapy has been shown in several randomised trials to improve disease-free (DFS) and overall survival (OS) in the postoperative setting for resected disease with poor prognostic factors.
Multiple randomised studies and meta-analyses have shown that definitive chemoradiotherapy, as well anti-epidermal growth factor receptor treatment in 1 randomised study, improved DFS and OS when compared with radiotherapy alone.

<< Previous
Expression of autotaxin and acylglycerol kinase in prostate...

Next >>
Thyroid tumours of uncertain malignant potential: frequency and...